
Glenmark Enters U.S. Sugammadex Market to Challenge $1.6 Billion Brand
With annual sales for the reference drug reaching $1.6 billion, the U.S. injectables market faces a new competitor as Glenmark Pharmaceuticals launches its generic Sugammadex Injection. The rollout aims to capture a significant share of the hospital segment by providing a therapeutically equivalent alternative to Merck’s established product.

























